Country: Canada
Language: English
Source: Health Canada
METOPROLOL TARTRATE
SIVEM PHARMACEUTICALS ULC
C07AB02
METOPROLOL
25MG
TABLET
METOPROLOL TARTRATE 25MG
ORAL
100/500
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0111923005; AHFS:
APPROVED
2015-07-03
PRODUCT MONOGRAPH PR METOPROLOL-L Metoprolol Tartrate Tablets, USP 25 mg, 50 mg and 100 mg Β-ADRENERGIC RECEPTOR BLOCKING AGENT Sivem Pharmaceuticals ULC 4705 Dobrin Street Saint-Laurent, Quebec H4R 2P7 www.sivem.ca DATE OF REVISION: March 31, 2021 SUBMISSION CONTROL NO.: 249498 _METOPROLOL-L Product Monograph _ _Page 2 of 39_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................17 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................24 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................24 PART II: SCIENTIFIC INFORMATION ...............................................................................26 PHARMACEUTICAL INFORMATION ..........................................................................26 DETAILED PHARMACOLOGY .....................................................................................27 TOXICOLOGY ..................................................... Read the complete document